Argus Forecasts Strong Price Appreciation for CVS Health (NYSE:CVS) Stock

CVS Health (NYSE:CVS) had its price objective boosted by stock analysts at Argus from $90.00 to $104.00 in a research report issued on Thursday,MarketScreener reports. The brokerage presently has a “buy” rating on the pharmacy operator’s stock. Argus’ price target would suggest a potential upside of 5.82% from the stock’s current price.

Several other analysts have also recently issued reports on the company. JPMorgan Chase & Co. upped their price objective on CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a research note on Tuesday. Wolfe Research dropped their price target on CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. DA Davidson raised their price objective on CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Bank of America lowered their target price on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research note on Tuesday, January 27th. Finally, Wells Fargo & Company raised their price target on shares of CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Twenty-two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, CVS Health presently has an average rating of “Moderate Buy” and an average price target of $98.08.

CVS Health Stock Up 0.2%

NYSE CVS opened at $98.28 on Thursday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health has a fifty-two week low of $58.35 and a fifty-two week high of $98.39. The business has a 50 day moving average price of $78.07 and a two-hundred day moving average price of $78.36. The stock has a market cap of $125.40 billion, a PE ratio of 43.20, a P/E/G ratio of 0.93 and a beta of 0.60.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same period last year, the firm earned $2.25 earnings per share. The company’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts predict that CVS Health will post 7.46 EPS for the current fiscal year.

Insider Activity at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.85% of the stock is owned by corporate insiders.

Institutional Trading of CVS Health

Institutional investors have recently modified their holdings of the company. Dickmeyer Boyce Financial Management Inc. bought a new position in CVS Health during the first quarter valued at about $371,000. Gibbs Wealth Management raised its position in CVS Health by 110.0% in the first quarter. Gibbs Wealth Management now owns 30,430 shares of the pharmacy operator’s stock worth $2,185,000 after acquiring an additional 15,937 shares in the last quarter. Sei Investments Co. lifted its holdings in CVS Health by 32.1% in the 1st quarter. Sei Investments Co. now owns 1,383,147 shares of the pharmacy operator’s stock valued at $99,338,000 after acquiring an additional 336,387 shares during the last quarter. Alamar Capital Management LLC bought a new position in shares of CVS Health during the 1st quarter valued at about $272,000. Finally, Arvest Bank Trust Division boosted its position in shares of CVS Health by 2,401.7% during the 1st quarter. Arvest Bank Trust Division now owns 66,945 shares of the pharmacy operator’s stock valued at $4,808,000 after purchasing an additional 64,269 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health received higher price targets from JPMorgan Chase ($111) and Sanford C. Bernstein ($106), signaling increased Wall Street confidence in the stock’s upside. Analyst Price Target Updates
• Positive Sentiment: Investors are still focused on CVS’s strong Q1 performance, with the company beating estimates on both EPS and revenue, which has helped support the share price. CVS Health Stock Hits a New 52-Week High After Posting Strong Q1 Results. Here’s Why It Can Still Go Even Higher
• Positive Sentiment: CVS Health and WGU launched a new online pre-pharmacy degree program, which could help build a stronger pharmacist pipeline and support long-term staffing needs. CVS Health® and WGU launch online pre-pharmacy degree program for future pharmacists nationwide
• Positive Sentiment: CVS Health’s Rhode Island stores now accept WIC for infant formula at all locations in the state, a small but supportive consumer-access initiative. All Rhode Island CVS Pharmacy Locations Now Accept WIC for Infant Formula
• Neutral Sentiment: CVS also won an AI industry award and highlighted operational technology improvements, but this is more of a long-term execution story than an immediate stock catalyst. CVS Health Wins Gold in Enterprise AI
• Negative Sentiment: Omnicare, a CVS subsidiary, received court approval to sell its business to GenieRx in bankruptcy proceedings, which underscores ongoing restructuring pressure in parts of CVS’s portfolio. CVS unit Omnicare wins court approval for sale to GenieRx

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.